Emergent BioSolutions (NYSE: EBS) awards 100,111 RSUs to EVP

Rhea-AI Filing Summary

Glessner Coleen reported acquisition or exercise transactions in this Form 4 filing.

Emergent BioSolutions Inc. reported that EVP of Quality & Ethics and CPL, Coleen Glessner, received a grant of 100,111 restricted stock units of common stock at no cost. The grant was approved by the Compensation Committee on March 2, 2026, contingent on stockholder approval of an Amended Stock Incentive Plan, which stockholders approved on April 29, 2026.

The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming Ms. Glessner continues her service with the company. Each unit represents one share of common stock, and following this award she holds 204,219 shares of common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Glessner Coleen

Role EVP, Quality & Ethics, and CPL

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	100,111	$0.00	--

Holdings After Transaction: Common Stock — 204,219 shares (Direct, null)

Footnotes (1)

1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Key Figures

RSUs granted: 100,111 restricted stock units Grant price: $0.0000 per share Shares after grant: 204,219 shares +3 more

6 metrics

RSUs granted 100,111 restricted stock units Grant to EVP Coleen Glessner on March 2, 2026 (approval date)

Grant price $0.0000 per share Awarded as compensation, not an open-market purchase

Shares after grant 204,219 shares Total common stock directly held following the award

Vesting schedule 3 annual installments Beginning on the anniversary of the approval date, assuming continued service

Committee approval date March 2, 2026 Compensation Committee approved grant, subject to stockholder approval

Stockholder approval date April 29, 2026 Stockholders approved the Amended Stock Incentive Plan

Key Terms

restricted stock units, Amended Stock Incentive Plan, Compensation Committee, vest in three annual installments, +1 more

5 terms

restricted stock units financial

"Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended Stock Incentive Plan financial

"subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan")"

Compensation Committee financial

"The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

vest in three annual installments financial

"These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval"

continued service financial

"beginning on the anniversary of the date of approval, assuming continued service with the Company."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glessner Coleen

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MARYLAND 20879

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Quality & Ethics, and CPL

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026	04/29/2026(1)	A		100,111(2)	A	$0	204,219	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

2. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Emergent BioSolutions (EBS) report for Coleen Glessner?

Emergent BioSolutions reported that EVP Coleen Glessner received a grant of 100,111 restricted stock units. These units were awarded at no cost and represent compensation rather than an open-market purchase, each unit convertible into one share of common stock under the company’s stock plan.

When was the Emergent BioSolutions (EBS) restricted stock unit grant approved?

The restricted stock unit grant was approved by the Compensation Committee on March 2, 2026. It was conditioned on stockholder approval of an amendment to the 2006 Stock Incentive Plan, which stockholders subsequently approved on April 29, 2026.

What plan governs the 100,111 restricted stock units granted by Emergent BioSolutions (EBS)?

The 100,111 restricted stock units were granted under Emergent BioSolutions’ Amended Stock Incentive Plan. This plan is an amendment to the company’s 2006 Stock Incentive Plan and became effective after stockholders approved the amendment on April 29, 2026.

How do the restricted stock units granted by Emergent BioSolutions (EBS) vest?

The restricted stock units vest in three annual installments beginning on the anniversary of the approval date. Vesting is conditioned on Coleen Glessner’s continued service with Emergent BioSolutions, aligning her long-term incentives with ongoing employment at the company.

How many Emergent BioSolutions (EBS) shares does Coleen Glessner hold after this grant?

Following the restricted stock unit award, Coleen Glessner holds 204,219 shares of Emergent BioSolutions common stock directly. This total reflects her position after the grant of 100,111 restricted stock units reported in the Form 4 insider filing.

What does each Emergent BioSolutions (EBS) restricted stock unit represent in this grant?

Each restricted stock unit represents the right to receive one share of Emergent BioSolutions common stock. This right is subject to vesting over three years and to other terms and adjustments set forth in the individual grant agreement under the Amended Stock Incentive Plan.